CoChat
Sign Up
Cited by 22Cervical Cancer and HPV ResearchReproductive tract infections researchWomen's cancer prevention and management

HPV genotype-specific concordance between EuroArray HPV, Anyplex II HPV28 and Linear Array HPV Genotyping test in Australian cervical samples

Open access
Cornall, Alyssa M., Poljak, Marin, Garland, Suzanne M., Phillips, Samuel, Machalek, Dorothy A., Tan, Jeffrey H., Quinn, Michael A., Tabrizi, Sepehr N.·2017·Papillomavirus Research
DOI 10.1016/j.pvr.2017.10.002PMC PMC5883236
Open this paper in CoChat — free accountOpen PDF

Abstract

PURPOSE: To compare human papillomavirus genotype-specific performance of two genotyping assays, Anyplex II HPV28 (Seegene) and EuroArray HPV (EuroImmun), with Linear Array HPV (Roche). METHODS: DNA extracted from clinican-collected cervical brush specimens in PreservCyt medium (Hologic), from 403 women undergoing management for detected cytological abnormalities, was tested on the three assays. Genotype-specific agreement were assessed by Cohen's kappa statistic and Fisher's z-test of significance between proportions. RESULTS: Agreement between Linear Array and the other 2 assays was substantial to almost perfect (κ = 0.60 - 1.00) for most genotypes, and was almost perfect (κ = 0.81 - 0.98) for almost all high-risk genotypes. Linear Array overall detected most genotypes more frequently, however this was only statistically significant for HPV51 (EuroArray; p = 0.0497), HPV52 (Anyplex II; p = 0.039) and HPV61 (Anyplex II; p=0.047). EuroArray detected signficantly more HPV26 (p = 0.002) and Anyplex II detected more HPV42 (p = 0.035) than Linear Array. Each assay performed differently for HPV68 detection: EuroArray and LA were in moderate to substantial agreement with Anyplex II (κ = 0.46 and 0.62, respectively), but were in poor disagreement with each other (κ = -0.01). CONCLUSIONS: EuroArray and Anyplex II had similar sensitivity to Linear Array for most high-risk genotypes, with slightly lower sensitivity for HPV 51 or 52.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.pvr.2017.10.002

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 38 · Cited by 22

Research works printed but not linked: 33

  1. [1]Dillner J. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study Br. Med. J. 377 2008 PMC2658827 18852164
  2. [2]Halec G. Pathogenic role of the eight probably/possibly carcinogenic HPV types 26, 53, 66, 67, 68, 70, 73 and 82 in cervical cancer J. Pathol. 234 2014 441 451 25043390
  3. [3]Whitaker J. Human papilloma virus type 69 identified in a clinically aggressive plantar verruca from an HIV-positive patient J. Am. Podiatr. Med. Assoc. 99 1 2009 8 12 19141715
  4. [4]FUTURE II Study Group Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions N. Engl. J. Med. 356 19 2007 1915 1927 17494925
  5. [5]Tota J.E. Evaluation of human papillomavirus type replacement post-vaccination must account for diagnostic artifacts: masking of HPV52 by HPV16 in anogenital specimens Cancer Epidemiol. Biomark. Prev. 24 1 2015 286 290 PMC4295012 25277793
  6. [6]Tabrizi S.N. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study Lancet Infect. Dis. 14 10 2014 958 966 25107680
  7. [7]Joura E.A. Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease Cancer Epidemiol. Biomark. Prev. 23 10 2014 1997 2008 25274978
  8. [8]Bruni L. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings J. Infect. Dis. 202 12 2010 1789 1799 21067372
  9. [9]Poljak M. Commercially available molecular tests for human papillomaviruses (HPV): 2015 update J. Clin. Virol. 76 S1 2015 S3 S13 26601820
  10. [10]Coutlée F. Use of PGMY primers in L1 consensus PCR improves detection of human papillomavirus DNA in genital samples J. Clin. Microbiol. 40 3 2002 902 907 11880413 PMC120235
  11. [12]Cornall A. EUROarray human papillomavirus (HPV) assay is highly concordant with other commercial assays for detection of high-risk HPV genotypes in women with high grade cervical abnormalities Eur. J. Clin. Microbiol. Infect. Dis. 35 6 2016 1033 1036 27048314
  12. [14]Stevens M.P. Comparison of the digene hybrid capture 2 assay and Roche AMPLICOR and LINEAR ARRAY human papillomavirus (HPV) tests in detecting high-risk HPV genotypes in specimens from women with previous abnormal pap smear results J. Clin. Microbiol. 45 7 2007 2130 2137 17494721 PMC1933009
  13. [15]Moore E.E. Clearance of human papillomavirus in women treated for cervical dysplasia Obstet. Gynecol. 117 1 2011 101 108 21173650
  14. [16]Phillips S. Comparison of the Roche Cobas® 4800 HPV assay to Digene Hybrid Capture 2, Roche Linear Array and Roche Amplicor for detection of high-risk human papillomavirus genotypes in women undergoing treatment for cervical dysplasia J. Clin. Virol. 62 2015 63 65 25542473
  15. [17]Stevens M.P. Assessment of MagNA Pure LC Extraction System for Detection of Human Papillomavirus (HPV) DNA in PreservCyt Samples by the Roche AMPLICOR and LINEAR ARRAY HPV Tests J. Clin. Microbiol. 44 7 2006 PMC1489532 16825360
  16. [18]Stevens M.P. Garland S.M. Tabrizi S.N. Development and validation of a real-time PCR assay specifically detecting human papillomavirus 52 using the Roche LightCycler® 480 system J. Virol. Methods 147 2 2008 290 296 17996311
  17. [19]Landis J.R. Koch G.G. The measurement of observer agreement for categorical data Biometrics 33 1 1977 159 174 843571
  18. [20]Stevens M.P. HPV genotype prevalence in women with abnormal pap smears in Melbourne, Australia J. Med. Virol. 81 7 2009 1283 1291 19475612
  19. [21]Poljak M. Nucleic acid tests for the detection of alpha human papillomaviruses Vaccine 30 S5 2012 F100 F106 23199952
  20. [22]Latsuzbaia A. Analytical performance evaluation of Anyplex II HPV28 and Euroarray HPV for genotyping of cervical samples Diagn. Microbiol. Infect. Dis. 85 3 2016 318 322 27156793
  21. [23]Gravitt P.E. Improved amplification of genital human papillomaviruses J. Clin. Microbiol. 38 1 2000 357 361 10618116 PMC88724
  22. [24]Chan P.K.S. Biases in human papillomavirus genotype prevalence assessment associated with commonly used consensus primers Int. J. Cancer 118 1 2006 243 245 16032705
  23. [25]Cornall A.M. In vitro assessment of the effect of vaccine-targeted human papillomavirus (HPV) depletion on detection of non-vaccine HPV types: implications for post-vaccine surveillance studies J. Virol. Methods 214 2015 10 14 25528202
  24. [26]Eklund C. Global proficiency study of human papillomavirus genotyping J. Clin. Microbiol. 48 11 2010 4147 4155 20844222 PMC3020877
  25. [27]Estrade C. Sahli R. Updating the PGMY primers and probes for improved detection of HPV68a: validation of Version 2 of the PGMY-CHUV assay J. Clin. Microbiol. 52 11 2014 4033 4035 25143570 PMC4313245
  26. [28]de Sanjose S. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study Lancet Oncol. 11 11 2010 1048 1056 20952254
  27. [29]Gravitt P.E. ICO monograph series on HPV and cervical cancer: general overview. New technologies in cervical cancer screening Vaccine 26 S10 2008 K42 K52 18847556
  28. [30]M. Arbyn, et al., Highlights Proceedings of the 27th International Papillomavirus Conference and Clinical Workshop: Part 2: Applied clinical science, Future Virol., 7 (1) 19-24.
  29. [32]Meijer C.J.L.M. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older Int. J. Cancer 124 3 2009 516 520 18973271 PMC2789446
  30. [34]Jung S. Clinical validation of Anyplex II HPV HR detection test for cervical cancer screening in Korea Arch. Pathol. Lab. Med. 140 3 2016 276 280 26927723
  31. [35]Agreda P.M. Long-term stability of human genomic and human papillomavirus DNA stored in BD SurePath and Hologic PreservCyt liquid-based cytology media J. Clin. Microbiol. 51 8 2013 2702 2706 23678069 PMC3719621
  32. [36]Kim Y. Stability of DNA, RNA, cytomorphology, and immunoantigenicity in Residual ThinPrep® Specimens Acta Pathol., Microbiol. Immunol. Scand. 121 11 2013 1064 1072 23566220
  33. [37]Arbyn M. Cervical cytology biobanking in Europe Int. J. Biol. Markers 25 3 2010 117 125 20872354

Authors
Cornall, A. M., Poljak, M., Garland, S. M., Phillips, S., Machalek, D. A., Tan, J. H., Quinn, M. A., & Tabrizi, S. N.
Affiliations
Royal Women's Hospital (AU)
Corresponding author
Cornall, Alyssa M.
ORCID
Venue
Papillomavirus Research
Publisher
Elsevier BV
Published
2017-12
Volume
4
Pages
79-84
ISSN
2405-8521 (ISSN-L)
DOI
10.1016/j.pvr.2017.10.002
PMC
PMC5883236
OpenAlex
W2765775872
Cited by
22
References
38
Citations by year
2026: 2 · 2025: 1 · 2024: 5 · 2023: 4 · 2022: 4 · 2021: 4 · 2019: 2
FWCI
0.43
Type
journal article
Language
en
Open access
Licence
Locations
  • Papillomavirus Research (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-nd)
Funders
Royal Women's Hospital Human Research and Ethics Committees (00/30)
Topics
  • Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
  • Life Sciences › Immunology and Microbiology › Microbiology › Reproductive tract infections research
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Women's cancer prevention and management
Keywords
human papillomavirus, HPV genotyping, assay concordance, cervical samples, high-risk HPV genotypes, HPV51, HPV52, HPV68, HPV42, assay sensitivity
MeSH terms
Australia, Cervix Uteri, DNA, Viral, Female, Genotype, Humans, Reagent Kits, Diagnostic, Sensitivity and Specificity, Polymerase Chain Reaction, Molecular Diagnostic Techniques, Papillomaviridae, Papillomavirus Infections, Genotyping Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review